 Treatment Groups Of the 100 women initially evaluated, 32 did not meet the inclusion and exclusion criteria, while eight refused to participate, giving a final total of 60 patients for inclusion in the study. The sixty postmenopausal women were randomly allocated into three groups: Group I: control group comprising 20 patients no hormonal treatment; Group II: also comprising 20 patients, to whom a continuous combined treatment with drospirenone 2 mg and 17β-estradiol 1 mg DRSPE2 will be administered daily; and Group III: also comprising 20 patients, to whom treatment with tibolone 1.25 mg Tib will be administered daily. All treatments will be administered for a 24-week period. DRSPE2 was purchased from Bayer Schering PharmaTM, Brazil and Tib from BiolabTM, Brazil. The duration of the treatment will be 6 cycles, each lasting a period of 28 days conducted for a total of 24 weeks. Randomization will be done with the aid of computer software in order to prevent bias in the selection process. 